Trial Profile
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 01 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 01 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.